Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.

Abstract

A one year double-blind trial of haloperidol decanoate and fluphenazine decanoate was conducted in nineteen out-patients who had previously received at least one year's treatment with fluphenazine decanoate and were already overweight, as judged by a Body Mass Index of 25+. Although the difference was not statistically significant, patients treated with haloperidol decanoate showed a trend to less weight gain than patients who continued on fluphenazine decanoate, even though the haloperidol to fluphenazine dose ratio was 4:1. No statistically significant changes in mental state were observed and the incidence of extrapyramidal side-effects in the two treatment groups was similar.

• Authors: J C Cookson, N M Kennedy, D Gribbon
• Journal: International clinical psychopharmacology (Int Clin Psychopharmacol) Vol. 1 Suppl 1 Pg. 41-51 (Jul 1986) ISSN: 0268-1315 [Print] England
• PMID: 3549879 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Delayed-Action Preparations
• Prolactin
• haloperidol decanoate
• fluphenazine depot
• Haloperidol
• Fluphenazine

Topics

• Adult
• Body Weight (drug effects)
• Clinical Trials as Topic
• Delayed-Action Preparations
• Double-Blind Method
• Female
• Fluphenazine (analogs & derivatives, therapeutic use)
• Haloperidol (analogs & derivatives, therapeutic use)
• Humans
• Male
• Middle Aged
• Prolactin (blood)
• Schizophrenia (drug therapy)